Robert Patrick Mahoney - May 19, 2022 Form 3/A - Amendment Insider Report for Comera Life Sciences Holdings, Inc. (CMRA)

Role
Chief Scientific Officer
Signature
/s/ Ryan M. Rourke Reed, Attorney-in-Fact
Stock symbol
CMRA
Transactions as of
May 19, 2022
Transactions value $
$0
Form type
3/A - Amendment
Date filed
2/14/2023, 04:18 PM
Date Of Original Report
May 20, 2022
Next filing
Feb 16, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CMRA Stock Option (Right to Buy) May 19, 2022 Common Stock 10.1K $0.59 Direct F1, F2
holding CMRA Stock Option (Right to Buy) May 19, 2022 Common Stock 15.4K $0.59 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 3/A is being filed to correct information previously disclosed on the original Form 3 filed by the reporting person on May 20, 2022, including disclosing the stock option grant as a single grant, the Date Exercisable, Expiration Date, Amount or Number of Shares, Exercise Price and vesting schedule of each grant. This Form 3/A also includes the reporting person's power-of-attorney.
F2 This option was issued pursuant to the terms of a business combination agreement involving the issuer and Comera Life Sciences, Inc. in exchange for a comparable option previously issued by such company on June 8, 2021. The option vests in 36 equal monthly installments beginning June 8, 2021.
F3 This option was issued pursuant to the terms of a business combination agreement involving the issuer and Comera Life Sciences, Inc. in exchange for a comparable option previously issued by such company on December 14, 2021. 25% of the option vests or vested on October 1, 2021 and in equal monthly installments thereafter for 36 months.

Remarks:

Exhibit 24 Power of Attorney filed herewith.